本文選題：太極集團 + 中藥�。� 參考：《西南財經(jīng)大學》2013年碩士論文

【摘要】：黨的十一屆三中全會以來,國家宏觀經(jīng)濟取得大發(fā)展、大繁榮,中國GDP超歐趕日,世界第二經(jīng)濟體的殊榮實至名歸。我國在全民醫(yī)療衛(wèi)生及健康保障方面也取得了實質(zhì)的進步,全民醫(yī)保積極推進、新醫(yī)改向縱深發(fā)展。人口老齡化加速、居民收入增長和健康意識增強,社會醫(yī)藥需求將快速增加,中國醫(yī)藥產(chǎn)業(yè)在2013至2022年將迎來持續(xù)高速發(fā)展的“黃金十年”。西藥研發(fā)成本越來越高、研發(fā)時間越來越長,安全性日益突出,而以“自然療法”提高生活品質(zhì)為特點的天然藥物產(chǎn)業(yè)將成為全球制藥業(yè)最具發(fā)展前景的優(yōu)勢產(chǎn)業(yè)。中藥產(chǎn)業(yè)是我國的特色傳統(tǒng)產(chǎn)業(yè),有深厚的歷史底蘊和群眾基礎(chǔ),老百姓對中醫(yī)藥的熱情逐年高漲。中藥因其確切療效、治未病、綜合調(diào)理、保健保養(yǎng)等特點恰好迎合老百姓對健康、長壽、美麗愿望的強烈需求,中藥產(chǎn)業(yè)必將迎來快速發(fā)展的春天。我國中藥產(chǎn)業(yè)50年前從零起步,經(jīng)過艱苦創(chuàng)業(yè)、開拓發(fā)展到今天逐步壯大成熟,為保障人民群眾的生命健康、提高生活質(zhì)量作出了巨大貢獻。進入21世紀,中醫(yī)藥產(chǎn)業(yè)在迅猛發(fā)展的同時,也不可避免地在藥品注冊、質(zhì)量標準、專利保護、行業(yè)監(jiān)管、研發(fā)生產(chǎn)、流通售后、參與國際競爭等方面出現(xiàn)了許多問題,這些問題如果不能及時有效地解決,必然會阻礙我國中醫(yī)藥產(chǎn)業(yè)的健康發(fā)展。 太極集團經(jīng)過近三十年的跨越式發(fā)展,從資產(chǎn)、產(chǎn)值都不足100萬元,甚至瀕臨倒閉的涪陵地方企業(yè),發(fā)展成今天資產(chǎn)過200億元,擁有三家上市公司,位列醫(yī)藥工業(yè)前十強,中藥制藥企業(yè)行業(yè)第一的領(lǐng)先地位,成為中國醫(yī)藥產(chǎn)業(yè)鏈最為完整的醫(yī)藥企業(yè)之一。但是最近幾年,快速發(fā)展的太極集團也遇到了體制僵化、管理落后、科研投入難以轉(zhuǎn)化為生產(chǎn)力、財務(wù)及生產(chǎn)管理成本過高,經(jīng)營效益低下、基礎(chǔ)建設(shè)薄弱、核心競爭力不突出、資金鏈緊張、發(fā)展瓶頸限制、經(jīng)營風險加大等問題,以上問題和不足嚴重影響到企業(yè)的健康發(fā)展,企業(yè)的千億太極戰(zhàn)略也只會停留在美好藍圖的層面上難以實現(xiàn)。 本文對太極集團發(fā)展概況,戰(zhàn)略環(huán)境與資源均衡做了系統(tǒng)科學的分析。得出太極集團在外部環(huán)境、內(nèi)部資源與能力等關(guān)鍵因素方面有以下機會和優(yōu)勢：良好的社會經(jīng)濟發(fā)展基礎(chǔ)；極大的中藥產(chǎn)業(yè)吸引力和增長潛力：國家、地方強有力的中藥產(chǎn)業(yè)扶持政策；科技進步、行業(yè)現(xiàn)代化發(fā)展趨勢明顯；太極集團極高的品牌知名度和行業(yè)美譽度；完備的中藥產(chǎn)業(yè)鏈、市場營銷網(wǎng)絡(luò)建設(shè)；充足的科研、產(chǎn)品、土地、人力資源儲備。同時也面臨以下的挑戰(zhàn)和劣勢：行業(yè)技術(shù)瓶頸及國際認可質(zhì)量標準難以建立；行業(yè)整體綜合競爭力弱；國際天然植物藥發(fā)展迅猛；現(xiàn)代中藥產(chǎn)業(yè)進展緩慢；各種原材料、能源、勞動力等資源價格上漲；集團管理跟不上規(guī)模的擴張；沒有建立科學高效的現(xiàn)代企業(yè)制度；集團負債過高、盈利和發(fā)展能力較低。綜合分析太極集團EFE矩陣輸出值為3.0,超過行業(yè)平均水平,表明公司目前面臨相當好的外部環(huán)境,公司對于外部環(huán)境的發(fā)展變化也有足夠的應(yīng)變能力,對于公司中遠期發(fā)展而言,應(yīng)該制定一體化的積極擴張型發(fā)展戰(zhàn)略；太極集團IFE矩陣輸出值為2.35,略低于2.5,即低于行業(yè)平均水平,表明公司內(nèi)部關(guān)鍵因素劣勢大于優(yōu)勢。因此公司應(yīng)該暫停多元化的發(fā)展戰(zhàn)略,整合優(yōu)勢資源,練好內(nèi)功,做大做強中藥主業(yè),提高自身核心競爭力,鞏固行業(yè)優(yōu)勢地位。 通過全面系統(tǒng)分析,科學論證,利用現(xiàn)代戰(zhàn)略選擇工具得出太極集團的正確發(fā)展戰(zhàn)略是：“中藥為本”!即以中藥制造、銷售為核心產(chǎn)業(yè),實施中藥大健康產(chǎn)業(yè)戰(zhàn)略,構(gòu)建中藥全產(chǎn)業(yè)價值鏈。進一步確定集團關(guān)鍵戰(zhàn)略環(huán)節(jié)為以冬蟲夏草為代表的稀缺及貴細中藥材的種植養(yǎng)殖及農(nóng)戶訂單式生產(chǎn)收購,獨家優(yōu)勢一、二平臺中藥工業(yè)產(chǎn)品的規(guī)模生產(chǎn)、全國推廣,強大的渠道配送及終端零售網(wǎng)絡(luò)。在工業(yè)產(chǎn)能布局上實行聚集式專業(yè)化生產(chǎn)戰(zhàn)略,商業(yè)布局理念上強調(diào)終端為王發(fā)展戰(zhàn)略,工商互動,為集團工業(yè)產(chǎn)品銷售插上騰飛的翅膀。在做強主業(yè)、夯實內(nèi)功的基礎(chǔ)上加快推進中藥現(xiàn)代化進程,并逐步進軍中藥大健康產(chǎn)業(yè)。產(chǎn)品結(jié)構(gòu)方面構(gòu)建T型產(chǎn)品線戰(zhàn)略,市場布局方面采取市場分級、梯度推進的重點市場優(yōu)先發(fā)展戰(zhàn)略。同時分析認為太極集團只要做好資源與環(huán)境建設(shè),改善組織結(jié)構(gòu),科學管理,確立好中藥全產(chǎn)業(yè)鏈戰(zhàn)略環(huán)節(jié),科研與營銷并重,加快集團現(xiàn)代中藥產(chǎn)業(yè)進程,緊抓市場機會,通過戰(zhàn)略聯(lián)盟及有效的資本運作,太極集團十年戰(zhàn)略目標一定會順利實現(xiàn)。一個中國植物藥制造業(yè)巨頭一定會引領(lǐng)祖國中醫(yī)藥文化走出國門,走向世界!
[Abstract]:Since the third Plenary Session of the 11th CPC Central Committee, the national macro economy has achieved great development, great prosperity, China's GDP super European drive to catch up with the day, the second economy of the world is well known. China has also made substantial progress in the health care and health protection of the whole people, the health insurance of the whole people has been actively promoted, the new medical reform has developed in a deep way. With the increase of income and health awareness, the demand for social medicine will increase rapidly. China's pharmaceutical industry will usher in a "golden ten year", which continues to develop rapidly from 2013 to 2022. The cost of Western medicine and development is increasing, the time for R & D is growing, and the security is increasingly prominent, and natural medicine, characterized by "natural therapy", is characterized by the improvement of the quality of life. The industry will become the most promising industry in the global pharmaceutical industry. The traditional Chinese medicine industry is the traditional industry with a profound historical and mass base. The enthusiasm of the common people is rising year by year. The characteristics of traditional Chinese medicine, due to its exact effect, treatment, comprehensive conditioning and health care, meet the health, longevity and beauty of the common people. The Chinese traditional medicine industry will have a rapid development in the spring of the Chinese traditional medicine industry. The Chinese traditional medicine industry started from zero 50 years ago. It has made great contributions to the people's life and health and the quality of life. The Chinese medicine industry has developed rapidly in twenty-first Century. Inevitably, there are many problems in drug registration, quality standards, patent protection, industry supervision, research and development, circulation and after-sale, and participation in international competition. If these problems can not be solved in time and effectively, the healthy development of Chinese traditional Chinese medicine industry will be hindered.
After nearly thirty years of leapfrog development, Taiji Group has developed from assets, less than 1 million yuan in output value and even on the verge of bankruptcy of Fuling local enterprises. It has developed into today's assets over 20 billion yuan, and has three listed companies. It is the top ten of the pharmaceutical industry and the first leading position in the pharmaceutical industry of Chinese medicine, which has become the most complete chain of Chinese pharmaceutical industry. But in recent years, the rapid development of Taiji Group has also encountered problems such as rigid system, backward management, difficult transformation of scientific research input into productive forces, high cost of financial and production management, low operating efficiency, weak infrastructure, lack of core competitiveness, shortage of capital chain, restriction of development bottleneck and increasing operational risk. The above problems and deficiencies seriously affect the healthy development of enterprises. The 100 billion Taiji strategy of enterprises will only remain at the level of the beautiful blueprint.
This paper makes a systematic and scientific analysis of the development of Taiji group, the strategic environment and the balance of resources, and concludes that the Taiji Group has the following opportunities and advantages in the aspects of external environment, internal resources and ability, such as the good social and economic development foundation, the great attraction and growth potential of the traditional Chinese medicine industry: the country and the local power The traditional Chinese medicine industry support policy; scientific and technological progress, the development trend of industry modernization is obvious; Taiji Group is very high brand awareness and industry reputation; complete Chinese medicine industry chain, marketing network construction; sufficient scientific research, products, land, human resources reserve. Meanwhile, the following challenges and disadvantages are also faced: industry technical bottleneck And the international accredited quality standards are difficult to be established; the overall competitiveness of the industry is weak; the development of international natural plant drugs is swift and violent; the development of modern traditional Chinese medicine industry is slow; the prices of various raw materials, energy, labor and other resources have risen; the management of the group can not keep up with the expansion of the scale; the scientific and efficient modern enterprise system has not been established; the group liability is not established. The EFE matrix output value of the Taiji Group is 3, exceeding the average level of the industry, which indicates that the company is facing a fairly good external environment and the company has sufficient strain ability for the development and change of the external environment. For the medium and remote development of the company, the integrated and active expansion should be formulated. Development strategy: the IFE matrix output value of Taiji Group is 2.35, slightly lower than 2.5, that is, lower than the industry average, which indicates that the company's internal key factors are more inferior than the advantages. Therefore, the company should suspend the diversification strategy, integrate the advantage resources, practice the internal skills, make the major Chinese medicine main industry, improve the core competitiveness of the company, and consolidate the advantages of the industry. Position.
Through comprehensive systematic analysis, scientific demonstration and the use of modern strategic choice tools, the correct development strategy of Taiji Group is as follows: "Chinese medicine is the base", which is made of traditional Chinese medicine, sales as the core industry, the implementation of Chinese traditional Chinese medicine industry strategy and the construction of the whole industry value chain of traditional Chinese medicine. The scarcity of the representative, the cultivation of traditional Chinese medicinal materials and the purchase and purchase of farmers' order type production, the exclusive advantage one, the scale production of the two platform Chinese medicine industrial products, the nationwide promotion, the powerful channel distribution and the terminal retail network. In the industrial production layout, the centralized and specialized production strategy is implemented, and the business layout concept emphasizes the terminal for Wang Fa. On the basis of strengthening the main industry and consolidating the internal work, we will accelerate the process of modernization of Chinese medicine on the basis of strengthening the main industry and consolidating the internal work, and step into the big health industry of traditional Chinese medicine. The product structure of the product line is built on the T product line strategy, the market layout takes market classification, and the key market with gradient promotion is the priority market priority. At the same time, it is believed that Taiji group should do well in the construction of resources and environment, improve the structure of the organization, scientific management, establish the strategic link of the whole industry chain of traditional Chinese medicine, attach importance to scientific research and marketing, accelerate the process of the modern traditional Chinese medicine industry, grasp the market opportunity, through the strategic alliance and effective capital operation, the ten year strategy of Taiji group. A Chinese herbal medicine manufacturing giant will lead the Chinese medicine culture to the world.

【學位授予單位】：西南財經(jīng)大學
【學位級別】：碩士
【學位授予年份】：2013
【分類號】：F272;F426.72

【參考文獻】

相關(guān)期刊論文 前1條

1 王學東;;中藥國際市場營銷環(huán)境[J];南通大學學報(社會科學版);2009年03期

，

本文編號：1832909